State-of-the-art chemoradiation is no substitution for trimodality approach in the treatment of locally advanced thoracic esophageal squamous cell carcinoma
Main Authors: | Hsin-Yi Yang, Kai-Sheng Liao, Cheng-Yen Lee, Kam-Hong Kam |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-08-01
|
Series: | Asian Journal of Surgery |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1015958423004013 |
Similar Items
-
Trimodal Therapy in Esophageal Squamous Cell Carcinoma: Role of Adjuvant Therapy Following Neoadjuvant Chemoradiation and Surgery
by: Xiaokun Li, et al.
Published: (2022-07-01) -
The impact of histological variants of urothelial carcinoma on clinical outcomes following trimodality bladder-sparing chemoradiation
by: Kiltie, A, et al.
Published: (2017) -
Prognostic significance of tumor regression grade in esophageal squamous cell carcinoma after neoadjuvant chemoradiation
by: Chi Zhang, et al.
Published: (2023-01-01) -
Definitive chemoradiation therapy or surgery for clinical T1-3N0-1M0 thoracic esophageal squamous cell carcinoma: A propensity score matching analysis
by: Xu-Yuan Li, et al.
Published: (2019-01-01) -
Definitive Chemoradiation with Concurrent Weekly Cisplatin in the Treatment of Esophageal Squamous Cell Carcinoma – A Simplistic Approach
by: Imtiaz Ahmed, et al.
Published: (2021-05-01)